Terms: = Ovarian cancer AND RARA, RAR, 5914, ENSG00000131759, NR1B1 AND Treatment
18 results:
1. Expression of selected nuclear receptors in human epithelial ovarian cell line Caov3 exposed to bisphenol derivatives.
Mlynarcikova AB; Macejova D; Scsukova S
Endocr Regul; 2023 Jan; 57(1):191-199. PubMed ID: 37715983
[No Abstract] [Full Text] [Related]
2. Targeting the Retinoic Acid Pathway to Eradicate cancer Stem Cells.
Brown G
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768694
[TBL] [Abstract] [Full Text] [Related]
3. Characterization of therapy-related acute leukemia in hereditary breast-ovarian carcinoma patients: role of BRCA1 mutation and topoisomerase II-directed therapy.
Bagal B; Kumar R; Gaur T; Talreja V; Bonda A; Patkar N; Shetty D; Kowtal P; Subramanian PG; Gupta S; Sarin R; Hasan SK
Med Oncol; 2020 Apr; 37(5):48. PubMed ID: 32277283
[TBL] [Abstract] [Full Text] [Related]
4. Inhibition of cancer stem cell like cells by a synthetic retinoid.
Chen J; Cao X; An Q; Zhang Y; Li K; Yao W; Shi F; Pan Y; Jia Q; Zhou W; Yang F; Wei F; Wang N; Yu B
Nat Commun; 2018 Apr; 9(1):1406. PubMed ID: 29643385
[TBL] [Abstract] [Full Text] [Related]
5. Age-related differences in the sonographic characteristics of endometriomas.
Guerriero S; Van Calster B; Somigliana E; Ajossa S; Froyman W; De Cock B; Coosemans A; Fischerová D; Van Holsbeke C; Alcazar JL; Testa AC; Valentin L; Bourne T; Timmerman D
Hum Reprod; 2016 Aug; 31(8):1723-31. PubMed ID: 27282774
[TBL] [Abstract] [Full Text] [Related]
6. An EGF receptor inhibitor induces rar-beta expression in breast and ovarian cancer cells.
Grunt TW; Puckmair K; Tomek K; Kainz B; Gaiger A
Biochem Biophys Res Commun; 2005 Apr; 329(4):1253-9. PubMed ID: 15766561
[TBL] [Abstract] [Full Text] [Related]
7. Activity of ALRT 1550, a new retinoid, with interferon-gamma on ovarian cancer cell lines.
Hu W; Verschraegen CF; Wu WG; Nash M; Freedman RS; Kudelka A; Kavanagh JJ
Int J Gynecol Cancer; 2002; 12(2):202-7. PubMed ID: 11975681
[TBL] [Abstract] [Full Text] [Related]
8. Regulation of aromatase by nuclear receptors.
Yanase T; Mu YM; Nishi Y; Goto K; Nomura M; Okabe T; Takayanagi R; Nawata H
J Steroid Biochem Mol Biol; 2001 Dec; 79(1-5):187-92. PubMed ID: 11850224
[TBL] [Abstract] [Full Text] [Related]
9. Cross-resistance to the synthetic retinoid CD437 in a paclitaxel-resistant human ovarian carcinoma cell line is independent of the overexpression of retinoic acid receptor-gamma.
Kumar A; Soprano DR; Parekh HK
Cancer Res; 2001 Oct; 61(20):7552-5. PubMed ID: 11606393
[TBL] [Abstract] [Full Text] [Related]
10. Drug approval summaries: arsenic trioxide, tamoxifen citrate, anastrazole, paclitaxel, bexarotene.
Cohen MH; Hirschfeld S; Flamm Honig S; Ibrahim A; Johnson JR; O'Leary JJ; White RM; Williams GA; Pazdur R
Oncologist; 2001; 6(1):4-11. PubMed ID: 11161223
[TBL] [Abstract] [Full Text] [Related]
11. Induction of apoptosis in ovarian carcinoma cells by AHPN/CD437 is mediated by retinoic acid receptors.
Holmes WF; Dawson MI; Soprano RD; Soprano KJ
J Cell Physiol; 2000 Oct; 185(1):61-7. PubMed ID: 10942519
[TBL] [Abstract] [Full Text] [Related]
12. Modulation of retinoic acid receptor function alters the growth inhibitory response of oral SCC cells to retinoids.
Le Q; Dawson MI; Soprano DR; Soprano KJ
Oncogene; 2000 Mar; 19(11):1457-65. PubMed ID: 10723137
[TBL] [Abstract] [Full Text] [Related]
13. Role of retinoic acid receptor overexpression in sensitivity to fenretinide and tumorigenicity of human ovarian carcinoma cells.
Pergolizzi R; Appierto V; Crosti M; Cavadini E; Cleris L; Guffanti A; Formelli F
Int J Cancer; 1999 May; 81(5):829-34. PubMed ID: 10328240
[TBL] [Abstract] [Full Text] [Related]
14. Critical role of both retinoid nuclear receptors and retinoid-X-receptors in mediating growth inhibition of ovarian cancer cells by all-trans retinoic acid.
Wu S; Zhang D; Zhang ZP; Soprano DR; Soprano KJ
Oncogene; 1998 Dec; 17(22):2839-49. PubMed ID: 9879990
[TBL] [Abstract] [Full Text] [Related]
15. Growth-inhibitory effects of the synthetic retinoid CD437 against ovarian carcinoma models in vitro and in vivo.
Langdon SP; Rabiasz GJ; Ritchie AA; Reichert U; Buchan P; Miller WR; Smyth JF
Cancer Chemother Pharmacol; 1998; 42(5):429-32. PubMed ID: 9771960
[TBL] [Abstract] [Full Text] [Related]
16. Retinoic acid receptor beta expression and growth inhibition of gynecologic cancer cells by the synthetic retinoid N-(4-hydroxyphenyl) retinamide.
Sabichi AL; Hendricks DT; Bober MA; Birrer MJ
J Natl Cancer Inst; 1998 Apr; 90(8):597-605. PubMed ID: 9554442
[TBL] [Abstract] [Full Text] [Related]
17. Effects of conformationally restricted synthetic retinoids on ovarian tumor cell growth.
Wu S; Zhang D; Donigan A; Dawson MI; Soprano DR; Soprano KJ
J Cell Biochem; 1998 Mar; 68(3):378-88. PubMed ID: 9518263
[TBL] [Abstract] [Full Text] [Related]
18. Overexpression of both rar and RXR restores AP-1 repression in ovarian adenocarcinoma cells resistant to retinoic acid-dependent growth inhibition.
Soprano DR; Chen LX; Wu S; Donigan AM; Borghaei RC; Soprano KJ
Oncogene; 1996 Feb; 12(3):577-84. PubMed ID: 8637715
[TBL] [Abstract] [Full Text] [Related]
